Cyclophosphamide: similarities and differences in the treatment of SSc and SLE

Abstract

Get full access to this article

View all access options for this article.

References

Varga

Trojanowska

Kuwana

. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Rel Disord 2017; 2: 137–152.

Ghodke-Puranik

Niewold

. Immunogenetics of systemic lupus erythematosus: a comprehensive review. J Autoimmun 2015; 64: 125–136.

Scherlinger

Guillotin

Truchetet

et al.

Systemic lupus erythematosus and systemic sclerosis: all roads lead to platelets. Autoimmun Rev 2018; 17: 625–635.

Kowal-Bielecka

Landewe

Avouac

et al.

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620–628.

Tashkin

Elashoff

Clements

et al.

Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655–2666.

Volkmann

Tashkin

et al.

Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol 2017; 69: 1451–1460.

Herrick

Pan

Peytrignet

et al.

Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis 2017; 76: 1207–1218.

van Laar

Farge

Sont

et al.

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490–2498.

Sullivan

Goldmuntz

Keyes-Elstein

et al.

Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 2018; 378: 35–47.

10.

Balbir-Gurman

Yigla

Guralnik

et al.

Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience. Isr Med Assoc J 2015; 17: 150–156.

11.

Matsumoto

Hayashi

Tahara

et al.

Intravenous cyclophosphamide for gastric antral vascular ectasia associated with systemic sclerosis refractory to endoscopic treatment: a case report and review of the pertinent literature. Intern Med 2019; 58: 135–139.

12.

Cappelli

Bellando-Randone

Guiducci

Matucci-Cerinic

. Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis? Rheumatology (Oxford) 2014; 53: 975–987.

13.

McCune

Golbus

Zeldes

Bohlke

Dunne

Fox

. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988; 318: 1423–1431.

14.

Austin

III Klippel

Balow

et al.

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614–619.

15.

Appel

Contreras

Dooley

et al.

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103–1112.

16.

Houssiau

Vasconcelos

D'Cruz

et al.

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121–2131.

17.

Takada

Illei

Boumpas

. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001; 10: 154–161.

18.

Borghini

Manetti

Nacci

et al.

Systemic sclerosis sera impair angiogenic performance of dermal microvascular endothelial cells: therapeutic implications of cyclophosphamide. PLoS One 2015; 10: e0130166.

19.

Furuya

Okazaki

Kaji

Sato

Takehara

Kuwana

. Mobilization of endothelial progenitor cells by intravenous cyclophosphamide in patients with systemic sclerosis. Rheumatology (Oxford) 2010; 49: 2375–2380.

20.

Volkmann

Chung

Tashkin

. Managing systemic sclerosis-related interstitial lung disease in the modern treatment era. J Scleroderma Relat Disord 2017; 2: 72–83.

21.

Gourley

Austin HA

III

Scott

et al.

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125: 549–557.

22.

Fernandez-Codina

Walker

Pope

on behalf of the Scleroderma Algorithm Group . Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol 2018; 70: 1820–1828.